Oncotelic Therapeutics Stock Fundamentals

OTLCDelisted Stock  USD 0.02  0  6.38%   
Oncotelic Therapeutics fundamentals help investors to digest information that contributes to Oncotelic Therapeutics' financial success or failures. It also enables traders to predict the movement of Oncotelic OTC Stock. The fundamental analysis module provides a way to measure Oncotelic Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncotelic Therapeutics otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Oncotelic Therapeutics OTC Stock Return On Equity Analysis

Oncotelic Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Oncotelic Therapeutics Return On Equity

    
  0.5  
Most of Oncotelic Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncotelic Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Oncotelic Therapeutics has a Return On Equity of 0.4967. This is 102.07% lower than that of the Healthcare sector and 101.36% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably lower than that of the firm.

Oncotelic Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Oncotelic Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncotelic Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncotelic Therapeutics competition to find correlations between indicators driving Oncotelic Therapeutics's intrinsic value. More Info.
Oncotelic Therapeutics is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Oncotelic Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oncotelic Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Oncotelic Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncotelic Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Oncotelic Therapeutics could also be used in its relative valuation, which is a method of valuing Oncotelic Therapeutics by comparing valuation metrics of similar companies.
Oncotelic Therapeutics is currently under evaluation in return on equity category among its peers.

Oncotelic Fundamentals

About Oncotelic Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Oncotelic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncotelic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncotelic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes and CA4P for the treatment of advanced metastatic melanoma. Oncotelic Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Consideration for investing in Oncotelic OTC Stock

If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
CEOs Directory
Screen CEOs from public companies around the world
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios